Jennifer Salvon

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.

Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.